Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2008 Oct;7(10):3256–3264. doi: 10.1158/1535-7163.MCT-08-0157

Figure 3.

Figure 3

Hsp70 contributes to Hsp90-directed therapy resistance. A: HeLa cells were transfected with control or Hsp70 siRNA as indicated, then plated for clonogenic assays. Cells were treated with GA for 24 h in concentrations indicated, then washed in serum-free medium and incubated in drug-free medium for 7 days to allow colonies to form. Error bars represent ± SEM, n=3. B: Hsp70+/+ and Hsp70−/− were plated for MTS assays, treated with vehicle (DMSO) or GA for 24 h in concentrations indicated, then washed and incubated in drug-free medium for 3 days. Absorbance was read to determine number of surviving cells. Error bars indicate ± SEM, n=3. C: Hsp70−/− were plated for MTS assays, treated with CDDP or 4 nM GA + CDDP in concentrations indicated for 24 h, then washed and incubated in drug-free medium for 3 days. Absorbance was read to determine number of surviving cells. Error bars indicate ± SEM, n=5.